Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in persistent post-traumatic headache
NCT03974360Phase 2Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erenumab in post-traumatic headache (PTH), sponsored by Dansk Hovedpinecenter. Primary endpoint: Effect of Erenumab on Headache Days with Moderate or Severe Intensity at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
erenumab
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT03974360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974360.